Lance A. Liotta

National Institutes of Health, George Mason University

Papers

2

Total Citations

135

H-Index

2

About

Lance A. Liotta is a pioneering figure in molecular pathology and proteomics, whose work has fundamentally advanced the early detection of cancer. His key research areas include serum proteomic profiling, laser capture microdissection (LCM), and the molecular analysis of disease from heterogeneous tissue samples. Liotta’s major contribution lies in developing artificial intelligence-based pattern recognition algorithms to analyze complex serum proteomic data, enabling the discrimination of prostate cancer from benign conditions in men with ambiguous PSA levels (2.5–15.0 ng/ml)—a breakthrough that has garnered 114 citations and reshaped diagnostic approaches. He also advanced the automation of LCM, a technique that isolates pure cell populations from tissue sections, allowing for precise molecular profiling of diseased versus healthy cells. This work, cited 21 times, has been instrumental in correlating proteomic data with tissue architecture. Liotta’s innovations have not only improved cancer diagnostics but also set the stage for personalized medicine, making him a transformative figure in translational research whose methods continue to guide students and researchers in the quest for non-invasive, accurate biomarkers.

Research Focus

Key Achievements

2
H-Index
2
Papers
135
Total Citations
68
Avg Citations/Paper
🏆 Most Cited Paper
SERUM PROTEOMIC PROFILING CAN DISCRIMINATE PROSTATE CANCER FROM BENIGN PROSTATES IN MEN WITH TOTAL PROSTATE SPECIFIC ANTIGEN LEVELS BETWEEN 2.5 AND 15.0 NG/ML
114 citations · 2004
📈 Most Prolific Year: 2004 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: National Institutes of Health, George Mason University

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago